New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:22 EDTGALE, LBIO, AVXT, GNBT, ARGSMaidstone Life Sciences to hold a conference
4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference is being held in New York on March 27.
News For LBIO;ARGS;AVXT;GALE;GNBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
11:31 EDTLBIOLion Biotechnologies TIL combo data an 'important' positive, says Piper Jaffray
After Lion Biotechnologies (LBIO) announced the report of positive results from a pilot trial of tumor infiltrating lymphocytes, or TIL, in combination with Bristol-Myers' (BMY) Yervoy in patients with metastatic melanoma, Piper Jaffray noted that the success rate for receiving TIL combo treatment was significantly higher than the prior result for TIL monontherapy. Piper said this fact highlights the combo approach may drive significantly broader application of TIL than it initially expected and the firm reiterated its Overweight rating and $21 price target on Lion shares.
08:39 EDTLBIOLion Biotechnologies announces positive data from TIL-ipilimumab study
Lion Biotechnologies announced that researchers from Moffitt Cancer Center reported positive results from a pilot trial of tumor infiltrating lymphocytes, or TIL, and ipilimumab in patients with metastatic melanoma. The data from the trial, which Lion partially sponsored, were presented at the Society of Surgical Oncology 2015 meeting in Houston, TX on Friday, March 27. The Phase 1 trial was conducted at Moffitt Cancer Center in 12 patients with metastatic melanoma, with the objective of determining the safety and feasibility of combining TIL therapy with the CTLA-4 checkpoint inhibitor, ipilimumab. Patients were treated with ipilimumab one week prior to tumor harvest for TIL expansion, a second time while their TIL were being expanded, and two more times following TIL transfer. Of the 12 patients enrolled in the trial, 11 went on to receive their autologous TIL, with five out of the 11 TIL-treated patients responding to treatment (one complete response and four partial responses), consistent with response rates from previous TIL studies in metastatic melanoma. Notably, the researchers observed that following a single infusion of ipilimumab, TIL grew to higher numbers than historically had been observed in previous studies, in which ipilimumab was not administered prior to tumor harvest. In addition, only one of the 12 enrolled patients was ineligible for TIL transfer, indicating relatively high patient adherence to trial protocol.
March 26, 2015
10:04 EDTARGSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:40 EDTARGSArgos Therapeutics initiated with a Buy at Roth Capital
Target $21.
07:16 EDTGALEGalena expands patient population in phase 2b NeuVax, trastuzumab trial
Subscribe for More Information
March 25, 2015
07:16 EDTARGSPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use